GlassScriptPhysician profile
Jessica Schneider
NPI 1063419273
$2,463.34
in general payments reported to CMS, 2019-2025
33 companies · $674 in 2025
The $674 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $71.99 · 2021: $87.22 · 2022: $474 · 2023: $552 · 2024: $223 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.98 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Agile Therapeutics, INC. | $154.02 | 2022-2024 | Twirla |
| Sage Therapeutics, LLC | $147.17 | 2025 | Zurzuvae |
| Gilead Sciences, INC. | $132.37 | 2019 | |
| Exeltis, USA INC. | $124.70 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $124.54 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $113.59 | 2022-2025 | |
| Pfizer INC. | $112.83 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $93.26 | 2021-2025 | |
| Astellas Pharma US INC | $86.11 | 2024 | Veozah |
| Evofem Biosciences, INC. | $83.34 | 2023-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $64.06 | 2023-2025 | Paragard T 380a |
| Allergan, INC. | $55.62 | 2019 | |
| Novo Nordisk INC | $55.10 | 2023-2025 | Wegovy |
| Baxter Healthcare | $48.50 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $40.05 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $37.98 | 2025 | Qelbree |
| Aspira Women'S Health INC | $37.92 | 2023 | Ova1 |
| Therapeuticsmd, INC. | $37.31 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.55 | 2023 | Givlaari |
| Vertical Pharmaceuticals, LLC | $26.83 | 2019-2020 | |
| Channel Medsystems, INC. | $25.19 | 2022 | |
| Myovant Sciences INC. | $24.78 | 2022 | |
| Hologic Sales and Service, LLC | $23.42 | 2024 | Aptima |
| Millicent US INC | $23.39 | 2025 | Femlyv, Intrarosa |
| Avion Pharmaceuticals | $21.46 | 2022 | |
| Ibsa Pharma INC. | $19.12 | 2025 | Flector, Tirosint, Licart |
| Scynexis, INC. | $19.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.76 | 2020 | |
| Medicem INC. | $14.32 | 2022 | |
| Ascend Therapeutics US, LLC | $13.46 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $13.29 | 2023 | Vivjoa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.